C Diff. Prevention Candidate Heads Into Clinic With Ambitious Timetable

Synthetic Biologics thinks it can produce first product to prevent C. difficile infections by protecting microbiome from impact of I.V. beta lactam antibiotics; biotech plans IND in next two months and hopes to produce proof-of-concept data within roughly one year.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from United States

More from North America